Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01046565 · ClinicalTrials.gov registry record · Phase 1
Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin
A Phase 1 study of Skin Manifestations, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT01046565: Completed Phase 1 study of Skin Manifestations, sponsored by Galderma R&D.
NCT01046565 is a Phase 1 study of Skin Manifestations that has completed, run by Galderma R&D. The registered enrollment target is 75 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01046565, a Phase 1 study of Skin Manifestations, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the tolerability of Differin® (adapalene) Cream, 0.1% to Differin® Lotion, 0.1% in subjects with healthy skin treated once a day for three (3) weeks.
Primary Outcome
Number of participants who were a success with regard to worst post-baseline tolerability assessment scores in each category of the tolerability assessments from baseline to week 3. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success for each category was defined as a tolerability score of 0.
Conditions Studied
Interventions
- DRUG adapalene cream 0.1%
- DRUG adapalene lotion 0.1%
Study Locations (1)
Texas
- Thomas J. Stephens & Associates, Inc. - Carrollton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
What the finished NCT01046565 record still lists
NCT01046565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher).
The record links to 1 condition, with Skin Manifestations appearing as the primary indexed condition, and to 2 interventions - of which adapalene cream 0.1% is the first listed.
NCT01046565 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01046565 about?
NCT01046565 is a clinical study titled "Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin". The purpose of this study is to compare the tolerability of Differin® (adapalene) Cream, 0.1% to Differin® Lotion, 0.1% in subjects with healthy skin treated once a day for three (3) weeks.
What is the current status of trial NCT01046565?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2010-01. Estimated completion is 2010-02.
What conditions does trial NCT01046565 study?
This clinical trial studies the following conditions: Skin Manifestations.
What interventions are being tested in trial NCT01046565?
The interventions under investigation include: adapalene cream 0.1% (DRUG), adapalene lotion 0.1% (DRUG).
Who is sponsoring clinical trial NCT01046565?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01046565 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Manifestations
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01046565's enrollment target sits among peer trials
75 711th of 2000 higher than 1,276 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia